Shenzhen Hepalink Pharmaceutical Group Co Ltd 股利資訊
Shenzhen Hepalink Pharmaceutical Group Co Ltd 每股年股息為 0.109,收益率為 0.00%。股息每 每年 支付,最後除權日為 May 26, 2025。
股息收益率
年度股息
除息日
0.00%
$0.109
May 26, 2025
付款頻率
派息比例
每年
0.00%
股利歷史
除息日
現金金額
記錄日期
付款日
May 26, 2025
$0.2717
May 27, 2025
Jul 22, 2025
May 24, 2023
$0.1122
May 25, 2023
Aug 15, 2023
Jun 14, 2022
$0.0411
Jun 15, 2022
Aug 15, 2022
股利圖表
SHEZF 股利
SHEZF 股息增長(年增率)
Follow-Up Questions
Shenzhen Hepalink Pharmaceutical Group Co Ltd 當前的股息支付和年度股息是多少?
Shenzhen Hepalink Pharmaceutical Group Co Ltd 的股息支付比率是多少?
SHEZF 的除息日是什麼?
Shenzhen Hepalink Pharmaceutical Group Co Ltd 多久支付一次股息?
關鍵數據
前收市價
$0.4696
開盤價
$0.7206
當日範圍
$0.4696 - $0.7206
52週區間
$0.4696 - $0.7206
交易量
25
平均成交量
0
每股盈餘 (TTM)
-0.02
股息收益率
--
市值
$103.3M
什麼是 SHEZF?
Shenzhen Hepalink Pharmaceutical Group Co Ltd is a CN-based company operating in Pharmaceuticals industry. The company is headquartered in Shenzhen, Guangdong and currently employs 1,926 full-time employees. The company went IPO on 2010-05-06. Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based company primarily engaged in the heparin industry chain, contract development and manufacturing organization (CDMO) of biological macromolecules, and the investment, development, and commercialization of innovative drugs. The firm operates four segments. The Pharmaceutical Formulations segment manufactures and sells enoxaparin sodium injection and others. The Active Pharmaceutical Ingredients (APIs) segment manufactures and sells standard heparin APIs, enoxaparin APIs and others. The CDMO segment provides process development services for pharmaceutical intermediates and APIs, including process research, optimization, analytical testing, and formulation research. The Other segment engages in other product businesses, such as pancreatic enzymes and casings. The firm conducts its business in the domestic and overseas markets.